Referências
1. Gadeyne C et al. Efficacy of oclacitinib (APOQUEL®) compared with prednisolone for the control of pruritus and clinical signs associated with allergic dermatitis in client-owned dogs in Australia. Vet Dermatol. 2014; 25: 512–e86.
2. Cosgrove SB et al. A blinded, randomized, placebo-controlled trial of the efficacy and safety of the Janus kinase inhibitor oclacitinib (APOQUEL®) in client-owned dogs with atopic dermatitis. Vet Dermatol 2013; 24: 587−e142.
3. APOQUEL® SPC.
4. Collard WT, Hummel BD, Fielder AF, King VL, Boucher JF, Mulins MA, Molaps PB, Stegemann MR. The pharmacokinetic of oclacitinib maleate, a Janus kinase inhibitor, in the dog. Journal of Veterinary Pharmacology and Therapeutics, 37(3):279–285, 2014.
5. Zoetis data on file, estudo interno 1462N-60-09-927.
*Fonte: Zoetis Global sell in data Apoquel and Cytopoint: 2013-2025.
**Informação extraída do site www.pubmed.com utilizando as palavras "Apoquel" e "oclacitinib" no campo de pesquisa. Acesso em 24/07/2026.

